How should the FDA balance faster access to new cancer drugs with the need for strong evidence that treatments help patients live longer or live better?
Dr. Robin Forrest and Dr. Huseyin Naci discuss their recent JAMA Network Open study examining how people with breast cancer view this trade-off—and when they believe uncertainty about a new drug’s benefits is, and is not, acceptable.